Active, Not Recruiting
Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients
NCT06403709
- Conditions
- Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, +9 more
- Locations
-
- Beijing Chaoyang Sanhuan Cancer Hospital Beijing, China